Protocol M15-991: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who failed Prior Biologic Treatment (Abbvie M15-

Project: Research project

Project Details

StatusFinished
Effective start/end date6/14/19 → 6/14/22

Funding

  • AbbVie Inc. (Prot#M15-991)